NZ765688B2 - Triphenylphosphonium-derivative compounds for eradicating cancer stem cells - Google Patents
Triphenylphosphonium-derivative compounds for eradicating cancer stem cells Download PDFInfo
- Publication number
- NZ765688B2 NZ765688B2 NZ765688A NZ76568818A NZ765688B2 NZ 765688 B2 NZ765688 B2 NZ 765688B2 NZ 765688 A NZ765688 A NZ 765688A NZ 76568818 A NZ76568818 A NZ 76568818A NZ 765688 B2 NZ765688 B2 NZ 765688B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- tpp
- cancer
- cells
- bis
- mitochondrial
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 69
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 64
- 201000011510 cancer Diseases 0.000 title claims abstract description 53
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 85
- 230000000694 effects Effects 0.000 claims abstract description 36
- 230000008685 targeting Effects 0.000 claims abstract description 25
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 13
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 13
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 12
- 238000001959 radiotherapy Methods 0.000 claims abstract description 8
- 206010027476 Metastases Diseases 0.000 claims abstract description 6
- 230000009401 metastasis Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 40
- 239000003112 inhibitor Substances 0.000 claims description 31
- 229940124597 therapeutic agent Drugs 0.000 claims description 31
- 230000002529 anti-mitochondrial effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000008437 mitochondrial biogenesis Effects 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000006545 glycolytic metabolism Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000004783 oxidative metabolism Effects 0.000 claims description 4
- 230000034659 glycolysis Effects 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 241000953757 Lunella Species 0.000 claims 1
- 239000012822 autophagy inhibitor Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 abstract description 53
- 230000002438 mitochondrial effect Effects 0.000 abstract description 30
- 210000002950 fibroblast Anatomy 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 206010059866 Drug resistance Diseases 0.000 abstract description 6
- 229940124650 anti-cancer therapies Drugs 0.000 abstract description 6
- 238000011319 anticancer therapy Methods 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000036284 oxygen consumption Effects 0.000 abstract description 5
- 230000002407 ATP formation Effects 0.000 abstract description 4
- 230000001464 adherent effect Effects 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 abstract description 4
- 230000011664 signaling Effects 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract 1
- 238000013459 approach Methods 0.000 description 26
- 230000003833 cell viability Effects 0.000 description 15
- 230000004898 mitochondrial function Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 230000001603 reducing effect Effects 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- -1 TPP) derivative compounds Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 241001559542 Hippocampus hippocampus Species 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000010867 Hoechst staining Methods 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 150000001345 alkine derivatives Chemical class 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000006686 mitochondrial oxygen consumption Effects 0.000 description 4
- 210000000441 neoplastic stem cell Anatomy 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 210000005102 tumor initiating cell Anatomy 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 150000002390 heteroarenes Chemical class 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000004099 Chlortetracycline Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 description 1
- 101000716763 Homo sapiens Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100020868 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 235000020934 caloric restriction Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- PQJQFLNBMSCUSH-SBAJWEJLSA-N chembl2364632 Chemical compound O=C1C2=C(O)[C@@](C(C(C(N)=O)=C(O)[C@H]3N(C)C)=O)(O)[C@H]3C[C@@H]2CC2=C1C(O)=CC=C2CN(C)OC PQJQFLNBMSCUSH-SBAJWEJLSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000022886 mitochondrial translation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001920 niclosamide Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 229950004150 omadacycline Drugs 0.000 description 1
- JEECQCWWSTZDCK-IQZGDKDPSA-N omadacycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O JEECQCWWSTZDCK-IQZGDKDPSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960005009 rolitetracycline Drugs 0.000 description 1
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229950000534 sarecycline Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 description 1
- 229960001897 stiripentol Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Tri-phenyl-phosphonium (TPP) is a non-toxic chemical moiety that functionally behaves as a mitochondrial targeting signaling in living cells. TPP-related compounds may be utilized to target mitochondria in cancer stem cells (CSCs), and may be used for treating and/or preventing tumor recurrence, metastasis, drug resistance, and/or radiotherapy resistance, as well as for anti- cancer therapies. Various TPP-related compounds validated for oxygen consumption inhibition (OCR), were non-toxic, and had little or no effect on ATP production in normal human fibroblasts. Yet these compounds selectively target adherent "bulk" cancer cells. These compounds also inhibit the propagation of CSCs in suspension. TPP-related compounds provide a novel chemical strategy for effectively targeting both i) "bulk" cancer cells and ii) CSCs, while specifically minimizing or avoiding off-target side-effects in normal cells, among other useful therapies. astasis, drug resistance, and/or radiotherapy resistance, as well as for anti- cancer therapies. Various TPP-related compounds validated for oxygen consumption inhibition (OCR), were non-toxic, and had little or no effect on ATP production in normal human fibroblasts. Yet these compounds selectively target adherent "bulk" cancer cells. These compounds also inhibit the propagation of CSCs in suspension. TPP-related compounds provide a novel chemical strategy for effectively targeting both i) "bulk" cancer cells and ii) CSCs, while specifically minimizing or avoiding off-target side-effects in normal cells, among other useful therapies.
Description
TRIPHENYLPHOSPHONIUM—DERIVATIVE COMPOUNDS FOR ERADICATING CANCER STEM CELLS FIELD This disclosure relates to nds and therapies for effectively targeting "bulk" cancer cells and cancer stem cells, while minimizing off-target side-effects in normal cells, and more particularly to tri-phenyl-phosphonium (TPP) derivative compounds, or TPP-derivatives, that potently target bulk cancer cells, cancer stem cells, and normal senescent cells, for delivery of therapeutic .
BACKGROUND Conventional cancer therapies, such as irradiation, alkylating agents, and anti- metabolites, work by selectively ating rowing cancer cells through interfering with cell growth and DNA replication mechanisms. Tumors often recur after such therapies, indicating that not all cancer cells were eradicated. Cancer stem cells (C SCs) are tumor-initiating cells (TICs) that appear to be the biological basis of treatment failure, tumor recurrence and distant metastasis, ultimately leading to poor clinical outcome in cancer ts. As a consequence, new therapies are urgently needed, to specifically target and eradicate CSCs.
Interestingly, recent studies indicate that one unique feature of CSCs is a characteristic increase in mitochondrial mass, which may reflect a more strict dependence on mitochondrial function or OXPHOS. Several ndent lines of evidence support the idea that increased mitochondrial biogenesis or higher levels of mitochondrial protein translation may occur in CSCs. For example, unbiased proteomics is directly shows that ondrial mass is elevated in CSCs.
[Annotation] KEB Moreover, MitoTracker (a mitochondrial fluorescent dye) can be used successfully as a marker to identify and purify CSCs. More specifically, the "Mito-high" cell population shows the st capacity for i) anchorage-independent growth and ii) tumor-initiating y in vivo.
High telomerase activity also directly correlates with high mitochondrial mass and the ability of CSCs to undergo proliferative ion. Similarly, high mitochondrial mass in CSCs was also specifically associated with mitochondrial reactive oxidative species (ROS) production (hydrogen peroxide) and could be targeted with either: i) mitochondrial anti-oxidants, ii) inhibitors of ondrial biogenesis (doxycycline) or OXPHOS, and even iii) inhibitors of cell proliferation (palbociclib, a CDK4/6 inhibitor).
There exists a need in the art for novel and effective anti-cancer therapies, including the development of not only new anti-cancer nds, but also methods for identifying new classes of compounds having anti-cancer efficacy. Ideal compounds are ive towards cancer cells, including TICs, yet non-toxic to normal cells. This also includes compounds and moieties that specifically target bulk cancer cells, cancer stem cells, and normal ent cells, for targeted delivery of therapeutic agents.
SUMMARY This disclosure describes a new approach for the eradication of CSCs and d therapies, h the use of novel mitochondrial inhibitors. sed herein are new strategies for identifying novel and non-toxic mitochondrial targeting signals, including the identity of specific compounds that may be used to enhance the anti-mitochondrial effects of other therapeutic agents. Disclosed herein are also demonstrative embodiments of TPP-conjugate compounds. ation] KEB Tri-phenyl-phosphonium (TPP) serves as a chemical mitochondrial targeting signal, and also represents a new avenue for safe and effective anti-cancer therapies. Described herein are TPP-derivative compounds that have been developed having a strong preference for uptake in cancer cells (e.g., bulk cancer cells, cancer stem cells, and energetic cancer stem cells), as well as normal but senescent cells. Importantly, TPP-derivatives described herein are non-toxic in healthy cells and normal f1broblasts, but potently target CSC propagation, with an IC-50 as low as 500 nM. As disclosed herein, TPP-derivative 2-butene-l,4-bis-TPP is an e of an effective TPP compound for targeting CSC propagation, among other potential therapies.
The t approach may be used to treat and/or prevent tumor recurrence, metastasis, drug resistance, and/or radiotherapy resistance. Anti-cancer treatments often fail because the tumor recurs or metastasizes, particularly after surgery. Also, drug resistance and radiotherapy resistance are common reasons for cancer treatment e. It is believed that CSC mitochondrial activity may be, at least in part, responsible for these causes of treatment failure.
Embodiments of the present approach may be used in situations where conventional cancer therapies fail, and/or in conjunction with anti-cancer ents to prevent failure due to tumor recurrence, asis, drug ance, and/or radiotherapy resistance. The t approach may also take the form of a method for targeting a therapeutic agent to a cancer stem cell mitochondria, by chemically modifying the therapeutic agent with at least one TPP-derivative compound.
As used herein, a TPP-derivative is a chemical nd derived from TPP. For example, a TPP-derivative compound may be 2-butene-l,4-bis-TPP, derivatives of 2-butene-l,4- bis-TPP, 2-chlorobenzyl-TPP, derivatives of 2-chlorobenzyl-TPP, 3-methylbenzyl-TPP, derivatives of 3-methylbenzyl-TPP, 2,4-dichlorobenzyl-TPP, tives of 2,4-dichlorobenzyl- TPP, l-naphthylmethyl-TPP, tives of l-naphthylmethyl-TPP, p-Xylylenebis-TPP, and [Annotation] KEB derivatives of lenebis-TPP. It should be appreciated that the foregoing list is not an exhaustive list of TPP-derivatives. As will be appreciated, however, the conjugated moiety(ies) can have a significant impact on whether the TPP-derivative has ancer or other beneficial properties, as well as the potency of those properties.
The present approach may take the form of a method for treating cancer, in which a pharmaceutically effective amount of at least one TPP-derivative compound is administered. The present approach may also take the form of methods and pharmaceutical compositions for treating and/or preventing tumor ence, metastasis, drug resistance, and/or radiotherapy resistance, in which a ceutically ive amount of at least one TPP-derivative compound is administered, either in conjunction with or after cancer therapy. The TPP-derivative compound may be administered with a mitochondrial inhibitor or other therapeutic agent, thereby increasing the agent’s uptake in cancer cells with little or no effect on normal, healthy cells. The TPP- derivative compound may be ne-l,4-bis-TPP, 2-chlorobenzyl-TPP, 3-methylbenzyl-TPP, 2,4-dichlorobenzyl-TPP, l-naphthylmethyl-TPP, or p-Xylylenebis-TPP. The TPP-derivative compound comprises 2-butene-l,4-bis-TPP in some embodiments. In some embodiments, there may be more than one TPP-derivative. In some embodiments, the rivative compound is one or more of: derivatives of 2-butene-l,4-bis-TPP, derivatives of 2-chlorobenzyl-TPP, derivatives of 3-methylbenzyl-TPP, tives of chlorobenzyl-TPP, derivatives of l- naphthylmethyl-TPP, and derivatives of p-Xylylenebis-TPP.
It should be appreciated that the TPP-derivative compound selectively targets cancer stem cells in embodiments of the present approach. Further, in some embodiments, the at least one TPP-derivative compound selectively targets normal senescent cells. TPP-derivative compounds may be minimally toxic or, in some embodiments, non-toxic, to normal healthy cells.
[Annotation] KEB The present approach may take the form of a ition , as an active ingredient, at least one TPP-derivative nd. For example, the pharmaceutical composition may be an anti-cancer pharmaceutical composition having, as its active ingredient, at least one TPP-derivative compound. The TPP-derivative compound comprises at least one of: 2-butene-l,4- bis-TPP, tives of2-butene-l,4-bis-TPP, robenzyl-TPP, derivatives of2-chlorobenzyl- TPP, 3-methylbenzyl-TPP, derivatives of 3-methylbenzyl-TPP, 2,4-dichlorobenzyl-TPP, tives of 2,4-dichlorobenzyl-TPP, l-naphthylmethyl-TPP, derivatives of l-naphthylmethyl- TPP, p-xylylenebis-TPP, and derivatives of p-xylylenebis-TPP. In some embodiments, for example, the active ingredient is 2-butene-l,4-bis-TPP. ments of the pharmaceutical ition may eradicate bulk cancer cells, cancer stem cells, and normal senescent cells. Further, the TPP-derivative compound may in embodiments of the present approach be non-toxic towards normal healthy cells.
TPP-derivatives may also ate senescent cells, thereby reducing and/or eliminating various aging-related es. The present approach may therefore take the form of a method for treating an affliction through administering a pharmaceutically effective amount of at least one TPP-derivative compound. The TPP-derivative compound may be administered with one or more additional therapeutic agents, such as agents having anti-mitochondrial effects. The affliction may be, for example, cancer, an age-associated illness, senescence-associated ory phenotype, or the effects of aging, such as atherosclerosis, cardiovascular disease, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes, obesity, metabolic syndrome, hypertension, Alzheimer's disease, chronic inflammation, neuro-degeneration, muscle-wasting (sarcopenia), loss of skin elasticity, greying of the hair, attern baldness, age spots, skin imperfections, and keratosis.
[Annotation] KEB BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1(A)-1(C) show the structures of nine TPP-derivatives, also referenced as TPP Compounds 1-9: A) shows: 1. 2-butene-1,4-bis-TPP; 2. 2-chlorobenzyl-TPP; 3. 3- methylbenzyl-TPP; B) shows: 4. 2,4-dichlorobenzyl-TPP; 5. 1-naphthylmethyl-TPP; 6. mito-TEMPO; and C) shows: 7. cyanomethyl-TPP; 8. p-Xylylene-bis-TPP; and 9. 4- enzyl-TPP.
FIGs. 2A and 2B show the effect of TPP-derivatives on cell ity and intracellular ATP levels in MCF-7 human breast cancer cells for TPP Compound 1 (2-butene-1,4- bis-TPP).
FIGs. 3A and 3B illustrate the e Effect of rivatives on cell viability and intracellular ATP levels in MCF-7 human breast cancer cells for TPP Compounds 2 (2- chlorobenzyl-TPP) and 3 (3 -methylbenzyl-TPP).
FIGs. 4A and 4B show the effect of TPP-derivatives on cell viability and intracellular ATP levels in MCF-7 human breast cancer cells for TPP Compounds 4 (2,4- dichlorobenzyl-TPP) and 5 (l-naphthylmethyl-TPP). rates the effects of rivatives on cell viability and intracellular ATP levels in normal fibroblasts (hTERT-BJ 1) and human breast cancer cells (MCF-7). illustrates impaired mitochondrial on of MCF-7 cells after treatment with TPP Compound 1 (2-butene-1,4-bis-TPP).
FIGs. 7A and 7B illustrate impaired mitochondrial function of MCF-7 cells after treatment with TPP Compounds 2 (2-chlorobenzyl-TPP) and 3 (3 -methylbenzyl-TPP).
FIGs. 8A and 8B show impaired mitochondrial function of MCF-7 cells after treatment with TPP Compounds 4 (2,4-dichlorobenzyl-TPP) and 5 (1-napthylmethyl-TPP).
[Annotation] KEB illustrates the differential inhibition of the mammosphere-forming activity of MCF-7 breast CSCs, after treatment with TPP-derivatives. shows a demonstrative approach for identifying mitochondrial inhibitors to target CSC propagation according to the present approach. rates a TPP Compound also referred to as bis-TPP. shows structural activity relationships for ed TPP-derivatives (A) 2- butene-l,4-bis-TPP, and (B) p-Xylene-bis-TPP.
DESCRIPTION The following ption illustrates embodiments of the present approach in sufficient detail to enable practice of the present approach. Although the present ch is bed with reference to these specific embodiments, it should be appreciated that the present ch may be embodied in different forms, and this description should not be ued as limiting any appended claims to the specific embodiments set forth herein. Rather, these ments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the present approach to those skilled in the art.
The inventors previously identified the approach of inhibiting mitochondrial function in CSCs and TICs as an avenue for eradicating cancer cells. Given the role of mitochondrial biogenesis in tumor proliferation, the inventors recognized that mitochondrial targeting represents a valuable characteristic for anti-cancer therapies. Tri-phenyl-phosphonium (TPP) is a well-established chemical mitochondrial targeting signal. Cargo molecules covalently attached to TPP accumulate within the mitochondria of living cells. However, sful anti- cancer therapies require targeting cancer cells, as d to normal cells. As discussed herein, [Annotation] KEB certain TPP-derivatives have been developed that not only selectively target cancer cell mitochondria, but also have minimal-to-no side-effects in normal cells.
In order to identify new molecules that can be used to target mitochondria within CSCs, the inventors screened a variety of rivatives as described herein, by employing CellTiter-Glo to measure intracellular levels of ATP in adherent cancer cells (MCF-7) in 96-well plates. As 85% of cellular ATP is normally derived from mitochondrial metabolism, ATP levels are an excellent read-out to monitor mitochondrial function. In parallel, the same 96-well plates were also stained with Hoechst 33342, to measure DNA content, to gauge cell viability. Therefore, we randomly selected 9 TPP derivatives and subjected them to screening in our assay system. The chemical structures of these TPP-derivatives are shown in Figure l.
TPP, as a mitochondrial targeting signaling, is non-toxic in normal cells. The ors recognized that TPP-derivative nds could be developed to inhibit mitochondrial function in CSCs, and developed the approach shown in Figure 10 for identifying such compounds.
To trate this ch, the inventors used an ATP depletion assay to screen the activity of the nine TPP-derivatives shown in Figure l, which e: (1) 2-butene-l,4-bis-TPP, (2) 2- chlorobenzyl-TPP, (3) 3-methylbenzyl-TPP, (4) 2,4-dichlorobenzyl-TPP, (5) thylmethyl- TPP, (6) mito-TEMPO (synonymous with (2-(2,2,6,6-Tetramethylpiperidin-l-oxylylamino) yl)triphenylphosphonium chloride), (7) cyanomethyl-TPP, (8) p-Xylylene-bis-TPP, and (9) 4-cyanobenzyl-TPP.
Five of the screened TPP-related compounds significantly suppressed ATP levels, which yields a hit-rate of more than 50%. All five positive hit compounds were subjected to functional validation with the Seahorse XFe96, to quantitate their effects on the mitochondrial oxygen ption rate (OCR). Remarkably, these TPP hit nds were non-toxic in normal [Annotation] KEB human fibroblasts and did not affect their viability or ATP tion, showing striking selectivity for cancer cells. Most importantly, these top hit compounds successfully blocked CSC ation, as shown by employing the 3D spheroid assay. For e, 2-butene-l,4-bis-TPP was that most potent molecule that we identified, which targeted CSC ation with an IC-50 < 500 nM. Interestingly, 2-butene-l,4-bis-TPP contains two TPP groups. This suggests that the use of a bis-TPP moiety, such as shown in Figure 11, may function as a "dimeric" or "polymeric" signal for the more effective targeting of mitochondria in CSCs. Further s are contemplated to continue exploring the potential of bis-TPP as a highly effective therapeutic agent.
Notably, five out of the nine TPP-derivative compounds were ive hits" that significantly reduced ATP levels. These positive hits included: 2-butene-l,4-bis-TPP, 2- chlorobenzyl-TPP, ylbenzyl-TPP, 2,4-dichlorobenzyl-TPP and l-naphthylmethyl-TPP.
This represents a hit rate of >50% of the TPP-derivatives subject to the demonstrative study.
However, two compounds were completely ineffective in reducing ATP levels (see Table 1). This finding is consistent with previous studies showing that the TPP moiety is not intrinsically toxic for normal cell mitochondria.
After initial screening, the five positive hit compounds were then subjected to further validation studies, shown in s 2-4, demonstrating that these TPP compounds are highly active in the range of 0.5 to 2 uM. Based on this initial analysis, 2-butene-l,4-bis-TPP demonstrated the t potency of the positive hit TPP-derivatives.
Figure 2A shows the effect of TPP Compound 1, 2-butene-l,4-bis-TPP, on cell viability and intracellular ATP levels in MCF-7 human breast cancer cells. Cell viability and ellular ATP levels were determined in the same treated samples. Hoechst staining (%) (shown in black bars), ATP levels (%) indicated in the white bars. MCF-7 cells were treated for ation] KEB 72h. Data are represented as mean +/- SEM. Note that 2-butene-l,4-bis-TPP depletes ATP levels, relative to cell number. >"*p < 0.01, >""""p < 0001, tes significance, all relative to the control.
Figure 2B shows a magnified image of control and treated cell plates. [003 6] Figures 3A and 3B show the effect of TPP Compound 2 (2-chlorobenzyl-TPP) and TPP Compound 3 (3-methylbenzyl-TPP) on cell viability and intracellular ATP levels in MCF-7 human breast cancer cells. Cell viability and ellular ATP levels were determined in the same treated samples. Hoechst staining (%) (shown in black bars), ATP levels (%) indicated in white bars. MCF-7 cells were treated for 72h. Data are represented as mean +/- SEM. Note that both 2- chlorobenzyl-TPP and 3-methylbenzyl-TPP progressively deplete cellular ATP levels. >"p < 0.05, >"*p < 0.01, >""""p < 0001, indicates significance, all relative to the control. [003 7] s 4A and 4B show the effect of TPP Compound 4 (2,4-dichlorobenzyl-TPP) and TPP Compound 5 (l-naphthylmethyl-TPP) on cell viability and intracellular ATP levels in MCF-7 human breast cancer cells. Cell viability and intracellular ATP levels were determined in the same treated samples. t staining (%) (shown in black bars), ATP levels (%) indicated in white bars. MCF-7 cells were treated for 72h. Data are represented as mean +/- SEM. Note that both 2,4-dichlorobenzyl-TPP and l-naphtylmethyl-TPP progressively deplete cellular ATP levels. >"p < 0.05, >"*p < 0.01, >""""p < 0001, tes significance, all relative to the control. [003 8] Figure 5 shows the effects of TPP-derivatives on cell viability and intracellular ATP levels in normal fibroblasts (hTERT-BJl) and human breast cancer cells (MCF-7). Cell viability and intracellular ATP levels were determined in the same treated samples. Hoechst staining (%) of hTERT-BJl human fibroblasts ), ATP level (%) of hTERT-BJl human fibroblasts (dotted), Hoechst staining (%) of MCF-7 cells (inclined lines), ATP level (%) of of MCF-7 cells [Annotation] KEB (white). TPP treatments at 1 uM, 72h. Data are represented as mean +/- SEM. >"p < 0.05, >"*p < 001, indicates significance, all relative to the control. [003 9] As can be seen in Figure 5, these TPP-derivatives are vely non-toxic in normal human fibroblasts (hTERT-BJl), but are preferentially active in cancer cells (MCF-7). For example, in human fibroblasts, ne-l,4-bis-TPP had no effect on cell viability and only mildly reduced ATP levels by 25%. In contrast, at the same concentration (1 M) in MCF-7 cancer cells, ne-l,4-bis-TPP reduced cell viability by nearly 65% and decreased ATP levels by almost 85%. ore, 2-butene-l,4-bis-TPP was 28-fold more effective at reducing cell viability in cancer cells (versus fibroblasts). Similarly, 2-butene-l,4-bis-TPP was 4.7-fold more effective at reducing ATP levels in cancer cells, relative to normal fibroblasts.
Some embodiments of the present approach relate to identifying TPP-derivatives compounds that target mitochondria in CSCs and represent potential ancer therapies. To further validate that the ATP level reduction of the TPP compounds was indeed due to the inhibition of mitochondrial function, we directly measured mitochondrial oxygen consumption rates (OCR) using the Seahorse XFe96 metabolic flux analyser. The results are shown in Figures 6-8. All five TPP Compounds behaved similarly, and effectively d basal ondrial respiration, with an IC-50 of approximately 1 uM. The identified TPP-derivatives also showed significant reduction in ATP-link respiration, maximal respiration, and spare respiratory capacity.
Figure 6 illustrates the impaired mitochondrial function of MCF-7 cells after ent with TPP Compound 1. Figures 7A and 7B illustrate the impaired mitochondrial on 7 cells after treatment with either TPP Compound 2 or TPP Compound 3. Figure 8 shows the impaired mitochondrial function of MCF-7 cells after ent with either TPP Compound 4 or TPP Compound 5. Oxygen consumption rate (OCR) was measured with a Seahorse XF96 [Annotation] KEB Extracellular Flux Analyzer. Data are represented as mean +/- SEM. Note that 2-butene-1,4-bis- TPP ively inhibits mitochondrial oxygen consumption. For Fig. 6, >""‘p < 0.01, >""""p < 0001, indicates significance, all relative to the control. Note that 2-chlorobenzyl-TPP and 3- methylbenzyl-TPP both effectively inhibit ondrial oxygen consumption. For Fig. 7, >"*p < 0.01, * >"*p < 0001, indicates significance, all relative to the control. Note that 2,4-dichlorobenzyl- TPP and 1-naphtylmethyl-TPP both effectively inhibit mitochondrial oxygen consumption. And for Fig. 8, >"*p < 0.01, >""""p < 0001, indicates 1cance, all relative to the l.
Following validation, the inventors evaluated the effects of these TPP-derivative compounds on the propagation of CSCs, using the mammosphere assay as a read-out. Figure 9 shows the differential tion of the mammosphere-forming activity of MCF-7 breast CSCs, after treatment with various TPP derivatives. The data presented in Figure 9, from left to right, are TPP-derivatives in the following order: 2,4-dichlorobenzyl-TPP (black), 1-naphthylmethyl-TPP (inclined lines), 3-methylbenzyl-TPP (dotted lines), 2-chlorobenzyl-TPP (white), 2-butene-1,4- bis-TPP (horizontal lines). Cells were treated for 5 days in mammosphere media. Data are represented as mean +/- SEM. Note that 2-butene-1,4-bis-TPP was the most effective nd for blocking CSC propagation, with an IC-50 less than 500 nM. >"p < 0.05, >"*p < 001, indicates signif1cance, all ve to the control.
Interestingly, 2-butene-1,4-bis-TPP was the most effective, with an IC-50 < 500 nM. In st, for two of the other compounds tested orobenzyl-TPP, 3-methylbenzyl- TPP) the IC-50 was between 1 to 5 uM. Finally, l-naphthylmethyl-TPP was the least potent, with an IC-50 > 5 uM. Therefore, the inventors concluded that 2-butene-1,4-bis-TPP is 2- to 10-fold more potent than the other TPP compounds, for targeting CSC propagation. This is despite the fact that the fied TPP-derivatives had nearly identical behavior in reducing mitochondrial ation] KEB respiration and ATP production. Therefore, r sic property of 2-butene-l,4-bis-TPP allows it to better target CSCs than the other TPP Compounds explored in the inventors’ confirmatory work.
Figure 10 shows an embodiment of the method according to the present approach: Identifying mitochondrial inhibitors to target CSC ation. First, at $1001, ctive compounds are selected from a library and subjected to ATP-depletion assays in cancer cells. As discussed above, the inventors selected TPP-related compounds as the starting point for screening, because this ensures that all the compounds tested are targeted to mitochondria. It should be appreciated by those of ordinary skill in the art that other TPP-related compounds, or other compounds containing moieties having a demonstrated or ed capacity for targeting the mitochondrial membrane, may be selected under the present approach. Compounds that reduce ATP levels are then identified $1002, and then may be functionally validated 81003 through, as an example, an is mitochondrial oxygen consumption rates (OCR) such as discussed above.
It should be appreciated that those having ordinary skill in the art may employ alternative assays to confirm that ATP level reduction of is due to the inhibition of mitochondrial function. Following validation, the effects of identified compounds on CSC proposition $1004 may be assessed. As discussed above, one embodiment of the t approach used mammosphere assays to assess CSC ation effects, though those having ordinary skill in the art may use alternative approaches to assess the efficacy of an identified compound for targeting CSCs. The outcome of this approach is the identification of new compounds having CSC inhibition effects. Beneficially, as applied in the confirmatory analysis described , the present approach demonstrates that the identified TPP-derivatives are mitochondrial inhibitors of CSCs that are non-toxic in normal human fibroblasts, thereby effectively limiting drug toxicity.
[Annotation] KEB Figure 11 shows TPP-derivative referred to as bis-TPP. This TPP-derivative is an effective mitochondrial targeting signal for eradicating cancer stem cells (CSCs). The "dimeric" structure of bis-TPP is shown in the drawing, where R represents a chemical group or moiety. For e, R may be selected from the group ting of hydrogen, carbon, en, sulfur, oxygen, e, chlorine, bromine, iodine, carboxyl, alkanes, cyclic s, alkane-based derivatives, alkenes, cyclic alkenes, alkene-based derivatives, alkynes, alkyne-based derivative, ketones, ketone-based derivatives, des, aldehyde-based derivatives, carboxylic acids, ylic acid-based derivatives, ethers, ether-based derivatives, esters and ester-based derivatives, amines, amino-based derivatives, , amide-based derivatives, monocyclic or clic arene, heteroarenes, arene-based derivatives, heteroarene-based derivatives, phenols, phenol-based derivatives, benzoic acid, and benzoic acid-based derivatives.
Figure 12 shows the structural activity relationships of ne-l,4-bis-TPP (see Figures 1 and 2) and p-xylylene-bis-TPP (see Figure l and Table l), the latter of which is approximately ZOO-fold less potent, in the context of ATP depletion. This demonstrates that while bis-TPP compounds may be effective for eradicating CSCs, some R groups may provide significantly more (or less) potency for targeting CSCs. Those having ordinary skill in the art will appreciate the need to evaluate each potential TPP-derivative compound’s potency.
Table 1. Four ineffective TPP Compounds. t stain ing ("{0} ATP level3 ("fa mito-TEMEPO* 1 {30.8 183.0 cyanomethyl-TPP 912 95 .1 4-cyanohenzyili-TPP 72.7 68 .2 p-xylylenebis-TPP 69.1 *il—i2.2,6,~‘5—tetr3m&thyluipet‘idEn-l—oztsf'lc‘; ‘f—B-oxoethy’l-TPP {E .3 vial. ‘ .§§uiar ATP lex 3 were determined in the same- treated samples.
Mif-E" cell line 5-3 gm? treatment for 72 hours. ation] KEB ation] KEB The following paragraphs describe the materials and methods used in connection with the prior discussion. It should be iated that those having at least an ordinary level of skill in the art will be familiar with these methods.
With respect to cell culture and reagents, the human breast adenocarcinoma cell line (MCF-7) was from the American Type Culture Collection (ATCC). hTERT-BJl cells were from Clontech, Inc. MCF-7 and hTERT-BJl cells were grown in DMEM supplemented with 10% fetal bovine serum, GlutaMAX and l% penicillin-streptomycin and incubated at 37C in a humidified 5% C02 tor. The medium was changed 2-3 week. The TPP derivatives were from Santa Cruz hnology, Inc., and included: (1) 2-butene-l,4-bis-TPP, (2) 2- chlorobenzyl-TPP, (3) 3-methylbenzyl-TPP, (4) 2,4-dichlorobenzyl-TPP, (5) l-naphthylmethyl- TPP, (6) mito-TEMPO, (7) cyanomethyl-TPP, (8) p-xylylene-bis-TPP, (9) 4-cyanobenzyl-TPP.
With respect to the ATP-depletion assay (with ter-Glo & Hoechst 33342), MCF-7 cells were treated with different TPP derivatives for 72 hours in a black 96-well plate then wells were washed with PBS and were stained with Hoechst 33342 dye at a final concentration of ug/ml. Fluorescence was read by a plate reader at 355 nm (excitation), 460 nm (emission).
After washing with PBS CellTiterGlo luminescent assay (Promega) was performed according to the manufacturer’s protocols to ine intracellular ATP levels in the Hoechst dye stained cells.
Both the fluorescent and luminescent data were normalized to l levels and were shown as percentage for comparison.
For measuring the mitochondrial OCR, mitochondrial function was determined by using the XF Cell Mito Stress Test Kit (Seahorse Bioscience, MA, USA) with a Seahorse XFe96 Extracellular Flux Analyzer (Seahorse Bioscience, MA, USA). MCF-7 cells were seeded in a specialized 96-well tissue culture plate (XF96 microplate). The next day, the TPP derivatives were [Annotation] KEB added and the plate was incubated for 72 hours. Before the experiment media was changed to XF base medium (including 1 mM pyruvate, 2 mM glutamine and 10 mM glucose), cells were incubated at 37°C in a CO2-free atmosphere for one hour before measurement. After detection of basal OCR (an indicator for mitochondrial respiration) OCR responses were evaluated towards the application of oligomycin (1 uM), FCCP (600 nM), and the combination of cin (1 uM) and rotenone (1 uM). From these measurements various parameters of mitochondrial function were determined. To determine cell viability in the measured wells sulphorodamine (SRB) assay was performed. Oxygen consumption rate values were then normalized to the given SRB values.
For the 3D Spheroid sphere) assay, a single cell suspension ofMCF-7 cells was ed using enzymatic (lx Trypsin-EDTA, Sigma Aldrich, #T3924) and manual disaggregation (25 gauge needle) to create a single cell suspension. Cells were plated at a density of 500 cells/cm2 in mammosphere medium Fl2 media ing B27/20 ng/ml and EGF/PenStrep) in non-adherent ions, in culture dishes coated with (2- hydroxyethylmethacrylate) (poly-HEMA, Sigma, #P3932). Different TPP derivatives were previously diluted in the mammosphere media before on of cells. Plates were maintained in a humidified incubator at 37°C at an atmospheric pressure in 5% (v/v) carbon dioxide/air. After 5 days of culture, spheres >50 um were counted using an eyepiece graticule and mammosphere numbers were normalized to l treatments (cells treated with vehicle only).
The foregoing ption demonstrates that TPP-related compounds represent a novel chemical strategy for ively targeting "bulk" cancer cells and CSCs, while minimizing off-target side-effects in normal cells. In this context, bis-TPP represents a more potent and selective form of TPP compounds, especially for targeting CSCs. Part of this potency and selectivity may also come from the reactive double bond in the central butene moiety, as p- [Annotation] KEB xylylene-bis-TPP (see Table 1 above) was ~200 times less effective than ne-1,4-bis-TPP (as shown in Fig. 2), in reducing overall ATP levels. Fig. 12 shows a side-by-side comparison of these two structures.
It should be appreciated that under the t approach, a therapeutic agent having an anti-mitochondrial , even if a side-effect or otherwise off-target property, may be used in connection with a TPP-derivative as an anti-cancer therapeutic. For example, TPP-derivatives may be administered covalently bonded with one or more therapeutic agents. The therapeutic agent may be a known pharmaceutical, ing, for example, an FDA-approved antibiotic or other drug that has itochondrial side-effects. The therapeutic agent may be a mitochondrial biogenesis inhibitor, such as cline, a boscin (mitoribosome-targeted therapeutics having anti-cancer and antibiotic properties), a mitoketoscin (non-carcinogenic compounds that bind to at least one of 2 and OXCT1/2 and inhibit mitochondrial ATP production), an antimitoscin (an antibiotic having intrinsic anti-mitochondrial properties that are chemically modified to target the antibiotics to mitochondria), as additional examples. International Patent Application , flled March 14, 2018, International Patent Application , filed May 18 2018, and International Patent Application 2018/039354, f11ed September 26, 2018, are each incorporated by reference in its entirety.
With respect to a mitoriboscin as a therapeutic agent, the agent may be a mitoribocycline, a mitoribomycin, a mitoribosporin, and/or a mitoribofloxin. The following compounds (or pharmaceutically acceptable salts thereof) are examples of agents that may be used: [Annotation] KEB ‘3'." 0’93: ,~"\ "NJ!" 3 ,3- R l i. \g'w" "Ni"? x; " i;_ i I! 3: k N~=A\...-" ‘" g ,3;"' «ff’l‘x { \l. 8 ‘ i§§.w‘""'\ R ."238‘ where each R may be the same or different and is selected from the group consisting of hydrogen, carbon, nitrogen, sulfur, , flourine, chlorine, bromine, iodine, carboxyl, alkanes, cyclic alkanes, -based derivatives, alkenes, cyclic alkenes, alkene-based derivatives, alkynes, alkyne-based derivative, s, ketone-based derivatives, aldehydes, aldehyde-based derivatives, carboxylic acids, carboxylic ased derivatives, ethers, ether-based tives, esters and ester-based derivatives, amines, amino-based derivatives, amides, amide-based derivatives, monocyclic or polycyclic arene, heteroarenes, arene-based derivatives, heteroarene- based derivatives, phenols, phenol-based derivatives, benzoic acid, benzoic acid-based derivatives, and one or more mitochondrial targeting signals. For clarif1cation, mitochondrial ing signals are defined as any chemical or peptide entity that increases the efficiency of targeting the ed molecule to the mitochondria. Such modif1cation would be expected to increase the potency and iveness of a mitoriboscin. Thus, R may be any mitochondrial targeting signal (peptide or chemical), including cationic compounds, such as tri-phenyl-phosphonium (TPP), a guanidinium- based moiety and/or choline esters, among others.
The therapeutic agent may comprise one or more of either or both an ive metabolism inhibitor and a ytic lism inhibitor. For example, an oxidative metabolism inhibitor may be a members of the tetracycline family and the erythromycin family. Members of ation] KEB the tetracycline family include tetracycline, doxycycline, tigecycline, minocycline, chlortetracycline, oxytetracycline, demeclocycline, lymecycline, meclocycline, ycline, rolitetracycline, chlortetracycline, omadacycline, and sarecycline. Members of the erythromycin family include erythromycin, azithromycin, and clarithromycin. Inhibitors of glycolytic metabolism may be selected from inhibitors of glycolysis, inhibitors of OXPHOS, and tors of autophagy. Inhibitors of glycolysis include 2-deoxy-glucose, ascorbic acid, and stiripentol.
Inhibitors of OXPHOS include atoravaquone, irinotecan, sorafenib, niclosamide, and berberine chloride. Inhibitors of autophagy include chloroquine.
It should be appreciated that one or more TPP-derivatives may be the active ient in a pharmaceutical composition. For example, the TPP-derivative may be ne- l,4-bis-TPP, derivatives of 2-butene-l,4-bis-TPP, 2-chlorobenzyl-TPP, tives of 2- chlorobenzyl-TPP, 3-methylbenzyl-TPP, derivatives of 3-methylbenzyl-TPP, 2,4-dichlorobenzyl- TPP, derivatives of 2,4-dichlorobenzyl-TPP, l-naphthylmethyl-TPP, tives of l- naphthylmethyl-TPP, p-Xylylenebis-TPP, and derivatives ofp-Xylylenebis-TPP. Those of ordinary skill in the art will appreciate that a "derivative" of a TPP-derivative is a compound formed from the identified TPP-derivative, and may include ural analogs. The composition and/or the TPP-derivative compound may be in the form of a , pill, powder, liquid, suspension, emulsion, e, capsule, suppository, injection preparation, solution, suspension, and/or a topical cream. The pharmaceutical composition may e a therapeutic agent having an anti- ondrial effect. The therapeutic agent may be covalently bonded to the TPP-derivative.
In addition to bulk cancer cells and CSCs, it should be appreciated that TPP- derivative compounds may be used to target a hyper-proliferative cell sub-population that the inventors refer to as energetic cancer stem cells (e-CSCs). e-CSCs show progressive increases in [Annotation] KEB ss markers (ALDH activity and mammosphere-forming activity), highly elevated mitochondrial mass, and increased glycolytic and mitochondrial activity.
It should also be appreciated that TPP-derivative nds may also have antibiotic and/or anti-senescence properties, among other valuable uses. For example, a TPP- derivative may be used for reducing or eliminating an age-associated illness such as atherosclerosis, cardiovascular disease, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes, obesity, metabolic syndrome, hypertension, Alzheimer's disease, chronic ation, neuro- degeneration, muscle-wasting (sarcopenia), loss of skin elasticity, greying of the hair, male-pattern baldness, age spots, skin ections, and keratosis. TPP-derivatives may also be used for preventing senescence-associated secretory ype. In such ments, the TPP-derivative may be administered with a therapeutic agent having an anti-mitochondrial effect. The embodiment may take the form of a pharmaceutical composition having at least one TPP- derivative and at least on therapeutic agent having an anti-mitochondrial effect. The therapeutic agent may be covalently bonded to the TPP-derivative(s). In such embodiments, the TPP- derivative may be administered with a eutic agent having an anti-mitochondrial effect. The embodiment may take the form of a pharmaceutical composition having at least one TPP- derivative and at least on therapeutic agent having an itochondrial effect. The therapeutic agent may be ntly bonded to the TPP-derivative(s).
Depending on the therapeutic agent, methods and compositions as described herein may also have radiosensitizing activity, photosensitizing activity, and/or may sensitive cancer cells to one or more of chemotherapeutic agents, natural substances, and/or caloric restriction.
Embodiments may also be useful for treating bacterial infection, pathogenic yeast infection, and aging. For example, the chemically modified therapeutic agent may also have enhanced anti-viral [Annotation] KEB activity, enhanced anti-bacterial ty, and/or enhanced anti-microbial activity. Thus, embodiments of the present approach may also be used for targeting virus replication, preventing or reducing the growth of pathogenic bacteria, yeast, and parasites, overcoming drug resistance in bacteria (e.g., methicillin-resistant Staph. Aureus, or MSRA).
TPP-derivatives may also be used for reducing the s of aging in an sm, treating at least one of atherosclerosis, vascular e, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes, obesity, lic syndrome, hypertension, and Alzheimer's disease, increasing lifespan, promoting tissue repair and regeneration, and reducing aging-associated inflammation.
The terminology used in the description of the invention herein is for the e of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms "a," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. The invention includes numerous alternatives, modifications, and equivalents as will become apparent from consideration of the following detailed description.
It will be understood that although the terms "first," "second," "third," "a)," "b)," and "c)," etc. may be used herein to describe various elements of the invention should not be limited by these terms. These terms are only used to distinguish one element of the invention from r. Thus, a first element discussed below could be termed an element aspect, and similarly, a third without departing from the teachings of the present invention. Thus, the terms "first," "second," "third," "a)," "b)," and "c)," etc. are not intended to necessarily convey a sequence or other chy to the associated elements but are used for identification purposes only. The sequence of operations (or steps) is not limited to the order presented in the claims.
[Annotation] KEB Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further tood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the t of the present application and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein. The terminology used in the description of the invention herein is for the e of describing particular embodiments only and is not intended to be limiting of the invention. All publications, patent applications, s and other references mentioned herein are incorporated by reference in their entirety. In case of a conflict in terminology, the present specification is controlling.
Also as used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or" Unless the context indicates otherwise, it is specifically intended that the various es of the ion described herein can be used in any combination. er, the present invention also contemplates that in some embodiments of the invention, any feature or combination of es set forth herein can be excluded or omitted. To illustrate, if the specification states that a x comprises components A, B and C, it is cally intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed.
As used herein, the transitional phrase "consisting essentially of’ (and grammatical variants) is to be interpreted as encompassing the recited materials or steps "and those that do not materially affect the basic and novel characteristic(s)" of the claimed invention. Thus, the term "consisting essentially of’ as used herein should not be reted as equivalent to "comprising." [Annotation] KEB The term "about," as used herein when referring to a measurable value, such as, for example, an amount or concentration and the like, is meant to encompass variations of :: 20%, %, 5%, l%, 0.5%, or even :: 0. l% of the specified amount. A range provided herein for a measureable value may e any other range and/or individual value therein.
Having thus described certain embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited by ular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope thereof as after claimed.
Claims (22)
1. Use of at least one TPP-derivative compound comprising at least one of: 2-butene- 1,4-bis-TPP; 2 obenzyl-TPP; ylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; 1- naphthylmethyl-TPP; and lenebis-TPP, in the manufacture of a medicament for treating at least one of a cancer tumor recurrence and a cancer metastasis, a drug resistant cancer, and a radiotherapy resistant cancer.
2. The use of claim 1, wherein the TPP-derivative compound comprises 2-butene- 1,4-bis-TPP.
3. The use of claim 1 or claim 2, wherein the ment further comprises at least one therapeutic agent having an anti-mitochondrial effect.
4. The use of claim 3, wherein the at least one therapeutic agent having an antimitochondrial effect comprises at least one of an antibiotic, a chemotherapeutic, a nutraceutical, a mitochondrial biogenesis inhibitor, a mitoriboscin, a toscin, a mitoribocycline, a mitoribomycin, a mitoribosporin, a mitoribofloxin, an oxidative metabolism inhibitor, and a glycolytic metabolism inhibitor.
5. Use of at least one TPP-derivative compound comprising at least one of: 2-butene- 1,4-bis-TPP; 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; 1 - naphthylmethyl-TPP; and p-xylylenebis-TPP, in the manufacture of a ment for preventing at least one of a cancer tumor recurrence and a cancer metastasis, a drug resistant cancer, and a radiotherapy resistant cancer.
6. The use of claim 5, wherein the medicament further comprises at least one therapeutic agent having an itochondrial effect.
7. The use of claim 6, wherein the at least one eutic agent having an tochondrial effect comprises at least one of an antibiotic, a chemotherapeutic, a eutical, a mitochondrial biogenesis inhibitor, a mitoriboscin, a mitoketoscin, a mitoribocycline, a mitoribomycin, a mitoribosporin, a mitoribofloxin, an oxidative metabolism inhibitor, and a glycolytic metabolism inhibitor.
8. Use of at least one TPP-derivative compound comprising at least one of: 2-butene- 1,4-bis-TPP; 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; 2,4 -dichlorobenzyl-TPP; 1- naphthylmethyl-TPP; and p-xylylenebis-TPP, in the manufacture of a medicament for treating cancer.
9. The use of claim 8, wherein the medicament r comprises at least one therapeutic agent having an anti-mitochondrial effect.
10. The use of claim 8 or claim 9, wherein the at least one TPP-derivative compound comprises 2-butene-1,4-bis-TPP.
11. The use of claim 8, wherein the at least one TPP-derivative compound selectively targets at least one of bulk cancer cells, CSCs, and energetic cancer stem cells.
12. The use of claim 11, wherein the at least one TPP-derivative compound ively targets normal senescent cells.
13. The use of claim 8, wherein the at least one TPP-derivative compound is xic to normal healthy cells.
14. The use of claim 9, wherein the at least one therapeutic agent having an antimitochondrial effect ses at least one of an antibiotic, a mitochondrial biogenesis inhibitor, a mitoriboscin, a mitoketoscin, a mitoribocycline, a bomycin, a mitoribosporin, a mitoribofloxin, an oxidative lism inhibitor, and a ytic metabolism inhibitor.
15. The use of claim 14, wherein the glycolytic metabolism tor comprises at least one of a glycolysis inhibitor, an OXPHOS inhibitor, and an autophagy inhibitor.
16. An anti-cancer pharmaceutical composition comprising at least one TPP- derivative compound comprising at least one of: 2-butene-1,4-bis-TPP; 2-chlorobenzyl-TPP; 3- methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; 1-naphthylmethyl-TPP; and p-xylylenebis-TPP said composition being formulated to be administered as an anti-cancer treatment.
17. The composition of claim 16, further comprising at least one therapeutic agent having an anti-mitochondrial effect.
18. The composition of claim 16 or claim 17, wherein the at least one TPP-derivative compound is 2-butene-1,4-bis-TPP.
19. The composition of claim 16, wherein the TPP-derivative nd is non-toxic towards normal healthy cells.
20. Use of a therapeutic agent chemically modified with at least one TPP-derivative nd comprising at least one of: 2-butene-1,4-bis-TPP; 2-chlorobenzyl-TPP; 3- methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; thylmethyl-TPP; and p-xylylenebis-TPP, in the manufacture of a ment for the treatment of cancer, via targeting the therapeutic agent to a cancer stem cell mitochondria, and wherein the eutic agent comprises at least one of an antibiotic, a mitochondrial biogenesis inhibitor, a mitoriboscin, a mitoketoscin, a mitoribocycline, a mitoribomycin, a mitoribosporin, a mitoribofloxin, an oxidative metabolism inhibitor, and a glycolytic metabolism inhibitor.
21. The use of claim 20, wherein the eutic agent has an anti-mitochondrial effect.
22. The use of claim 20, wherein the chemically modified therapeutic agent comprises at least one of enhanced anti-viral activity, enhanced anti-bacterial activity, and enhanced antimicrobial activity relative to the eutic agent lacking said cation. Lunella Biotech, Inc. By the patent attorneys for the applicant SPRUSON & FERGUSON
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ779976A NZ779976A (en) | 2017-11-24 | 2018-11-21 | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762590432P | 2017-11-24 | 2017-11-24 | |
US62/590,432 | 2017-11-24 | ||
PCT/US2018/062174 WO2019104115A1 (en) | 2017-11-24 | 2018-11-21 | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ765688A NZ765688A (en) | 2021-09-24 |
NZ765688B2 true NZ765688B2 (en) | 2022-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11738034B2 (en) | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells | |
CA3060510A1 (en) | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) | |
AU2018270129A1 (en) | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells | |
CN108309977B (en) | Application of indole ethylene substituted quinoline derivative in preparation of drug-resistant bacteria resistant drugs | |
WO2009006555A2 (en) | Methods, composition, targets for combinational cancer treatments | |
Li et al. | Composition, antivirulence activity, and active property distribution of the fruit of Terminalia chebula Retz | |
CN114984019B (en) | Iron death inhibitor compound and application thereof in liver injury repair field | |
KR20210072026A (en) | Azithromycin and hydroxythromycin derivatives as senolytic drugs | |
Zhou et al. | Cooperative Membrane Damage as a Mechanism for Pentamidine–Antibiotic Mutual Sensitization | |
NZ765688B2 (en) | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells | |
JP2006517204A (en) | Use of active ingredients for the prevention and / or treatment of viral diseases | |
BR112021011963A2 (en) | TRIPLE COMBINATION THERAPIES FOR MITOCHONDRIA TARGETING AND CANCER STEM CELL EXTERMINATION | |
CA3101198A1 (en) | Biomarkers and therapeutics for endocrine therapy resistance | |
WO2021024208A1 (en) | Tpp-derivatives for mitochondria-targeted cancer therapies | |
BR112021006569A2 (en) | macrocyclic compounds and uses thereof | |
Zhang et al. | Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance | |
Pulbutr et al. | Inhibitory activity of lupinifolin isolated from Derris reticulata stem against biofilm formation of Streptococcus mutans and Staphylococcus aureus | |
KR20180136679A (en) | Pharmaceutical composition for preventing or treating choriocarcinoma comprising luteolin | |
Kurvonen | Miniaturization of a screening method to find novel inhibitors of E. coli efflux pumps | |
Nass | Revisiting unexploited natural products in search of new antibacterial drug candidates: the case of the benzoisochromanequinone and dithiolopyrrolone classes | |
GuiYing et al. | The Inhibition of Nrf2/NQO1 pathway was involved in Polymyxin B Exerts Nephrotoxicity Effects in vivo and in vitro | |
Kim | Development of guanidine derivatives and CO-releasing agents: a novel approach in the treatment of drug resistant bacterial infections | |
Kumar et al. | Inhibitors of Efflux Pumps | |
Yulak | Investigation of The Antiproliferative Effect of Colchicine on SNU-1 Gastric Cancer Cells | |
SUSMITA | IN VITRO STUDIES ON THE EFFECT OF CAFFEIC ACID ON THE ANTIBACTERIAL ACTIVITY OF SELECTED CEPHALOSPORINS |